



Mitiadous O, Hou M, Bussel JB. Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment. *Blood*. 2020;135(7):472-490.

Under “Combination treatment to manage refractory patients with ITP,” in the last paragraph on page 478, the first combination treatment discussed is a selection of C-MOPP, CEP, or CVP (not CHOP, as originally stated). The regimen consisted of 3 to 8 cycles of therapy with cyclophosphamide and prednisone combined with either vincristine (CVP; 1 patient), vincristine and procarbazine (C-MOPP; 4 patients), or etoposide (CEP; 6 patients, including 1 patient who received 4 cycles of procarbazine and etoposide). McMillan⁴⁵ reported the longer follow-up of those patients and included 4 additional patients. The error has been corrected in the online version of the article.

DOI 10.1182/blood.202006529

© 2020 by The American Society of Hematology